-

01:18:31 AM

PLRX Stock News

PLRX - Pliant Therapeutics Inc

02/02/23 8:02 AM

Nasdaq : PLRX

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of

RHEA-AI

neutral

01/27/23 4:03 PM

Nasdaq : PLRX

offering

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the closing of its previously announced upsized

RHEA-AI

neutral

01/25/23 8:01 AM

Nasdaq : PLRX

management

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced Ms. Lily Cheung as its Chief Human Resources

RHEA-AI

neutral

01/24/23 9:19 PM

Nasdaq : PLRX

offering

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underwritten public

RHEA-AI

neutral

01/23/23 4:01 PM

Nasdaq : PLRX

offering

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that it has commenced an underwritten public

RHEA-AI

neutral

01/22/23 2:00 PM

Nasdaq : PLRX

clinical trial

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No bexotegrast-treated patients experienced disease progression as defined by FVCpp decline of greater than or equal to 10% Bexotegrast was well tolerated over 12

RHEA-AI

neutral

01/03/23 8:00 AM

Nasdaq : PLRX

conferences

Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and

RHEA-AI

neutral

12/15/22 8:00 AM

Nasdaq : PLRX

Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics (NASDAQ: PLRX) announced today that its lead drug candidate, bexotegrast (PLN-74809), an oral, once daily, dual-selective αvß6/αvß1 integrin inhibitor, has received Orphan Drug Designation from the European

RHEA-AI

very positive

11/15/22 8:00 AM

Nasdaq : PLRX

conferences

Pliant Therapeutics to Participate in Upcoming Investor Conferences

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following November investor

RHEA-AI

neutral

11/08/22 4:02 PM

Nasdaq : PLRX

earnings

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2022

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

PLRX Data

IndustryMedicinal and Botanical Manufacturing
Websitepliantrx.com
CeoBernard Coulie
Security namePliant Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees78
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Medicinal and Botanical Manufacturing
Address260 Littlefield Avenue
Address2Suite 150
StateCalifornia
CitySouth San Francisco
Zip94080
CountryUS
Phone16504816770

About Pliant Therapeutics Inc

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.